The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Viracta Therapeutics Appoints Michael Faerm As Chief Financial Officer
PRIVATEMay 14, 2024•about 2 years ago
Position
Chief Financial Officer
Company
Viracta Therapeutics
Michael Faerm
Cardiff By The SeaInformation TechnologyBiotechnologyHealth CareScience And Engineering
Description
Viracta Therapeutics, Inc announced the appointment of Michael Faerm as Chief Financial Officer. Mr Faerm, a seasoned biotech executive with over 25 years of experience, is expected to play a key role in supporting the company's next phase of development.
Company Information
Company
Viracta Therapeutics
Location
Cardiff By The Sea, California, United States
About
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma and one Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
Cardiff By The SeaInformation TechnologyBiotechnologyHealth CareScience And Engineering